The Motley Rice Antitrust Practice Group continues to be recognized as one of the nation’s foremost plaintiffs’ antitrust class action practices

Two 2023 Motley Rice generic drug antitrust class action settlements have been applauded in the newly released Antitrust Annual Report. The report, which is published by the Center for Litigation and Courts at U.C. Law San Francisco and the Huntington National Bank, highlights firms achieving significant results in antitrust litigation.

Out of 32 antitrust settlements approved in 2023, Motley Rice served as co-lead counsel in the ninth (Zetia) and sixteenth (Suboxone) largest cases. Additionally, Motley Rice attorneys represented the largest class action retailer in the number one listed case (Visa/Mastercard).

“This report recognizes the level of excellence we pursue in our antitrust cases and the success we achieve for the benefit of our clients,” said Michael M. Buchman, Motley Rice antitrust group lead and New York office managing attorney.

Review the 2023 Antitrust Annual Report.

Congratulations to the entire Antitrust Practice Group for their notable achievement and continued leadership in the plaintiffs’ class action antitrust bar.